ArticleBMC veterinary research2026
Exploration of the effect and mechanism of indirubin on infectious bovine rhinotracheitis virus based on network pharmacology.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Exploration of the effect and mechanism of indirubin on infectious bovine rhinotracheitis virus based on network pharmacology.BMC veterinary research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
backgroundOur team’s previous research indicates that infectious bovine rhinotracheitis virus (IBRV) induces mitochondrial damage in bovine kidney cells (MDBK). Indirubin, a bisindole alkaloid, can alleviate mitochondrial damage. However, it is currently unclear whether indirubin can regulate mitochondrial damage caused by IBRV in MDBK cells.
resultsThis study predicted the anti-IBRV effect of indirubin through network pharmacology, verified its anti-IBRV activity through experiments, and confirmed that indirubin can alleviate mitochondrial damage caused by IBRV. Network pharmacological results show that 81 potential targets of indirubin in infectious bovine rhinotracheitis (IBR) have been screened through network analysis. The analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) shows that the anti-IBR activity of indirubin involves multiple signaling pathways. Genetic ontology (GO) analysis reveals that its anti-IBR effect encompasses a variety of biological functions, with 15 target genes enriched in mitochondria. Virus suppression experiments have shown that indirubin can inhibit IBRV virus replication in MDBK cells. Flow cytometry showed that indirubin can reduce the elevated levels of reactive oxygen species (ROS) and depolarization of mitochondrial membrane potential (MMP) caused by IBRV infection. The molecular docking results confirm that indirubin exhibits a strong binding affinity with 15 targets.
conclusionsOur research shows that indirubin may exert anti-IBRV properties by regulating the production of ROS and inhibiting MMP depolarization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.